The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Medina, Reinhold J ^a   O'Neill, Christina L ^a   Devine, Adrian B ^a   Gardiner, Tom A ^a   Stitt, Alan W ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; NITRIC OXIDE; PROTEIN KINASE B; SIMVASTATIN; VASCULOTROPIN; ACTIN; HYPOCHOLESTEROLEMIC AGENT; ONCOPROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIUM CELL; EYE TOXICITY; ISCHEMIA; LOW DRUG DOSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; RETINOPATHY; VASCULAR ENDOTHELIUM; ANIMAL; BIOSYNTHESIS; CATTLE; CELL MOTION; DIABETIC RETINOPATHY; DRUG EFFECT; METABOLISM; PHOSPHORYLATION;

ACTINS; ANIMALS; ANTICHOLESTEREMIC AGENTS; CATTLE; CELL MOVEMENT; CELL PROLIFERATION; CHOLESTEROL; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ISCHEMIA; NITRIC OXIDE; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; SIMVASTATIN;

EID: 50249141649     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002584     Document Type: Article

References (46)

1. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart-disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307.
3. Sacks EM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009.
4. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22.
5. Bonetti PO, Lerman LO, Napoli C, Lerman A (2003) Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 24: 225-248.
6. NIH (2006) Statins for the prevention of cardiovascular events: Technology Appraisal Guidance 94. London.
7. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117-125.
8. Cheung BM (2008) Statins for people with diabetes. Lancet 371: 94-95.
9. Watkins PJ (2003) Retinopathy. Bmj 326: 924-926.
10. Mizutani M, Kern TS, Lorenzi M (1996) Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 97: 2883-2890.
11. Stitt AW, McGoldrick C, Rice-McCaldin A, McCance DR, Glenn JV, et al. (2005) Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes 54: 785-794.
12. Frank RN (2004) Diabetic retinopathy. N Engl J Med 350: 48-58.
13. Tawfik HE, El-Remessy AB, Matragoon S, Ma G, Caldwell RB, et al. (2006) Simvastatin improves diabetes-induced coronary endothelial dysfunction. J Pharmacol Exp Ther 319: 386-395.
14. Sen K, Misra A, Kumar A, Pandey RM (2002) Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 56: 1-11.
15. Zhang J, McGwin G Jr (2007) Association of statin use with the risk of developing diabetic retinopathy. Arch Ophthalmol 125: 1096-1099.
16. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, et al. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010.
17. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, et al. (2002) 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 91: 143-150.
18. Urbich C, Dernbach E, Zeiher AM, Dimmeler S (2002) Double-edged role of statins in angiogenesis signaling. Circ Res 90: 737-744.
19. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, et al. (2001) Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 89: 866-873.
20. Fujio Y, Walsh K (1999) Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274: 16349-16354.
21. Dimmeler S. Fleming I, Fisslthaler B, Hermann C, Busse R, et al. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605.
22. Jacobson JR, Dudek SM, Birukov KG, Ye SQ, Grigoryev DN, et al. (2004) Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol 30: 662-670.
23. Navarro A, Anand-Apte B, Parat MO (2004) A role for caveolae in cell migration. Faseb J 18: 1801-1811.
24. Parat MO, Anand-Apte B, Fox PL (2003) Differential caveolin-1 polarization in endothelial cells during migration in two and three dimensions. Mol Biol Cell 14: 3156-3168.
25. Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2: 517-526.
26. Thavendiranathan, P, Bagai A, Brookhart MA, Choudhry NK (2006) Primary prevention of cardiovascular, diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 166: 2307-2313.
27. Gordon B, Chang S, Kavanagh M, Berrocal M, Yannuzzi L, et al. (1991) The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 112: 385-391.
28. Badr GA, Tang J, Ismael-Beigi F, Kern TS (2000) Diabetes downregulates GLUT1 expression in the retina and its microvessels but not in the cerebral cortex or its microvessels. Diabetes 49: 1016-1021.
29. Moon JC, Bogle RG (2006) Switching statins. Bmj 332: 1344-1345.
30. Lilja JJ, Neuvonen M, Neuvonen PJ (2004) Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 58: 56-60.
31. Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic effects on angiogenesis. Circulation 105: 739-745.
32. Rikitake Y, Liao JK (2005) Rho GTPases, statins, and nitric oxide. Circ Res 97: 1232-1235.
33. Ii M, Losordo DW (2007) Statins and the endothelium. Vascul Pharmacol 46: 1-9.
34. Chen SD, Hu CJ, Yang DI, Nassief A, Chen H, et al. (2005) Pravastatin attenuates ceramide-induced cytotoxicity in mouse cerebral endothelial cells with HIF-1 activation and VEGF upregulation. Ann N Y Acad Sci 1042: 357-364.
35. Matsuno H, Takei M, Hayashi H, Nakajima K, Ishisaki A, et al. (2004) Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries. J Cardiovasc Pharmacol 43: 333-340.
36. Frick M, Dulak J, Cisowski J, Jozkowicz A, Zwick R, et al. (2003) Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis 170: 229-236.
37. Shiojima I, Walsh K (2002) Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90: 1243-1250.
38. Morales-Ruiz M, Fulton D, Sowa G, Languino LR, Fujio Y, et al. (2000) Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res 86: 892-896.
39. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
40. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, et al. (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597-601.
41. van Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW (2003) Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol 23: 211-217.
42. Wolfrum S, Jensen KS, Liao JK (2003) Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 23: 729-736.
43. Boukhtouche F, Mariani J, Tedgui A (2004) The "CholesteROR" protective pathway in the vascular system. Arterioscler Thromb Vasc Biol 24: 637-643.
44. Ikonen E (2006) Mechanisms for cellular cholesterol transport: defects and human disease. Physiol Rev 86: 1237-1261.
45. Coleman G, Gardiner TA, Boutaud A, Stitt AW (2007) Recombinant alpha2(IV)NC1 domain of type IV collagen is an effective regulator of retinal capillary endothelial cell proliferation and inhibits pre-retinal neovascularisation. Graefes Arch Clin Exp Ophthalmol 245: 581-587.
46. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, et al. (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35: 101-111.